These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions. Rizzo N; Padoin C; Palombo S; Scherrmann JM; Girre C Eur J Clin Pharmacol; 1996; 49(6):491-5. PubMed ID: 8706775 [TBL] [Abstract][Full Text] [Related]
25. Rapid effect of lansoprazole on intragastric pH: a crossover comparison with omeprazole. Thoring M; Hedenström H; Eriksson LS Scand J Gastroenterol; 1999 Apr; 34(4):341-5. PubMed ID: 10365892 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. Mainz D; Borner K; Koeppe P; Kotwas J; Lode H J Antimicrob Chemother; 2002 Nov; 50(5):699-706. PubMed ID: 12407126 [TBL] [Abstract][Full Text] [Related]
27. Effects of proton pump inhibitors on thyroid hormone metabolism in rats: a comparison of UDP-glucuronyltransferase induction. Masubuchi N; Hakusui H; Okazaki O Biochem Pharmacol; 1997 Dec; 54(11):1225-31. PubMed ID: 9416973 [TBL] [Abstract][Full Text] [Related]
28. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Sakai T; Aoyama N; Kita T; Sakaeda T; Nishiguchi K; Nishitora Y; Hohda T; Sirasaka D; Tamura T; Tanigawara Y; Kasuga M; Okumura K Pharm Res; 2001 Jun; 18(6):721-7. PubMed ID: 11474773 [TBL] [Abstract][Full Text] [Related]
29. Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Kokufu T; Ihara N; Sugioka N; Koyama H; Ohta T; Mori S; Nakajima K Eur J Clin Pharmacol; 1995; 48(5):391-5. PubMed ID: 8641328 [TBL] [Abstract][Full Text] [Related]
30. Lansoprazole does not affect the bioavailability of oral contraceptives. Fuchs W; Sennewald R; Klotz U Br J Clin Pharmacol; 1994 Oct; 38(4):376-80. PubMed ID: 7833230 [TBL] [Abstract][Full Text] [Related]
31. Lansoprazole: in the management of gastroesophageal reflux disease in children. Scott LJ Paediatr Drugs; 2003; 5(1):57-61; discussion 62. PubMed ID: 12513106 [TBL] [Abstract][Full Text] [Related]
32. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. Gunasekaran T; Gupta S; Gremse D; Karol M; Pan WJ; Chiu YL; Keith R; Fitzgerald J J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S327-35. PubMed ID: 12607793 [TBL] [Abstract][Full Text] [Related]
33. Morning versus evening dosing of lansoprazole 30 mg daily on twenty-four-hour intragastric acidity in healthy subjects. Fraser AG; Sawyerr AM; Hudson M; Smith MS; Pounder RE Aliment Pharmacol Ther; 1996 Aug; 10(4):523-7. PubMed ID: 8853755 [TBL] [Abstract][Full Text] [Related]
34. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249 [TBL] [Abstract][Full Text] [Related]
35. Esomeprazole: a review of its use in the management of acid-related disorders. Scott LJ; Dunn CJ; Mallarkey G; Sharpe M Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317 [TBL] [Abstract][Full Text] [Related]
36. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Angiolillo DJ; Gibson CM; Cheng S; Ollier C; Nicolas O; Bergougnan L; Perrin L; LaCreta FP; Hurbin F; Dubar M Clin Pharmacol Ther; 2011 Jan; 89(1):65-74. PubMed ID: 20844485 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. Calabresi L; Pazzucconi F; Ferrara S; Di Paolo A; Tacca MD; Sirtori C Pharmacol Res; 2004 May; 49(5):493-9. PubMed ID: 14998561 [TBL] [Abstract][Full Text] [Related]
38. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095 [TBL] [Abstract][Full Text] [Related]
39. A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers. Jovanović D; Kilibarda V; Maksimović M Pharmazie; 2001 Oct; 56(10):800-2. PubMed ID: 11683127 [TBL] [Abstract][Full Text] [Related]
40. Influence of lansoprazole on intragastric 24-hour pH, meal-stimulated gastric acid secretion, and concentrations of gastrointestinal hormones and enzymes in serum and gastric juice in healthy volunteers. Brunner G; Hell M; Hengels KJ; Hennig U; Fuchs W Digestion; 1995; 56(2):137-44. PubMed ID: 7750667 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]